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Abstract
We report a case of a patient presenting with a triad of hypercalcemia, metabolic alkalosis and renal
failure secondary to calcium bicarbonate intake for osteoporosis prevention. It is the classical
presentation of the “modern” milk alkali syndrome that presents several characteristics distinguishing
it from the “old” syndrome described secondary to peptic ulcer disease treatment. Milk alkali
syndrome affects middle-aged female patients taking over-the-counter calcium carbonate. Clinically,
these patients present in an acute hypercalcemia crisis, responding rapidly to hydration. The
phosphorus level is normal to low. Bisphosphonate should be used cautiously due to the risk of
symptomatic hypocalcemia.
Introduction
In 1912, Sippy described a “cure” for gastric ulcer
consisting of milk and antacid (calcium carbonate,
sodium bicarbonate, magnesium oxide and bismuth
subcarbonate) [1]. During the following three decades,
several case reports of complications secondary to the high
calcium and bicarbonate content of this solution lead to
the description of three clinical “milk alkali syndrome”
(MAS) [2,3]: acute, subacute (Cope’s syndrome) and
chronic (Brunett’s syndrome) [4]. After the advent of
non absorbable antacids and later histamine-2 blockers,
the incidence of this syndrome dropped to less than 1% of
etiologies of hypercalcemia in the mid-seventies [5].
During the last 2 decades, cases of MAS have been reported
frequently and the authors suggested that this syndrome is
reemerging (incidence of MAS as a cause of hypercalcemia
was reported in new series to be as high as 12%, the third
leading cause of hypercalcemia) [6,7]. The epidemiology
and the etiology of MAS changed. We report a case of this
“modern version” of MAS.
Case presentation
Our patient is an 81-year-old white male, citizen of United
States, who presented to our hospital for a one week
history of lethargy and nausea. The day of admission, he
developed an acute change in mental status, and became
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known to have hypertension, diabetes mellitus and benign
prostate hypertrophy. On physical examination, the
patient was severely cachectic and disoriented. His vital
signs were in the normal range except for a high blood
pressure of 200/100 mmhg.
The initial blood tests on admission showed a creatinine of
8.3mg/dlandaserumcalciumconcentrationof14.6mg/dl.
Two months previously the patient had a creatinine of
1.2 mg/dl and a serum calcium concentration of 8.9 mg/dl.
In addition, the patient presented with metabolic alkalosis.
Theadmissiondiagnosiswashypercalcemialeadingtoacute
renal failure and contraction metabolic alkalosis.
After aggressive saline hydration for 2 days, the patient
regained his baseline level of consciousness, the serum
calcium concentration returned to normal values. How-
ever, the glomerular filtration rate did not recover and was
still less than 10 ml/min. The patient was started on
hemodialysis for 2 sessions and then stopped upon the
patient’s request to stop all additional therapy and he
opted for hospice care. A repeat laboratory test in four
weeks after his hospital discharged showed a glomerular
filtration rate of 47 ml/min and a serum creatinine of
1.2 mg/dl implying a spontaneous resolution of his acute
renal failure (Table 1).
The diagnosis was established on a repeat interview with
the patient after he regained his orientation in which he
admitted taking an estimate of twenty five tablets of
calcium carbonate every day as a self medication for
osteoporosis prevention. Our final diagnosis is hypercal-
cemia secondary to milk alkali syndrome.
Discussion
MAS consists of a triad of hypercalcemia, metabolic
alkalosis and renal insufficiency associated with the
ingestion of large amounts of calcium and absorbable
alkali. Classically described as secondary to treatment of
peptic ulcer disease with Sippy’s regimen, in the modern
version of milk alkali syndrome the source of calcium is
usually calcium carbonate given for several indications
(osteoporosis treatment and prevention, phosphate bin-
der in renal failure, with glucocorticoid therapy). In the Far
East, Asia and South Pacific, MAS could be induced by
betel nut chewing [8,9].
MAS has changed from a middle-aged male dominated
condition [10] to one with more than half of the patients
being female of an average age of 50 years [11]. The
diagnosis is based on a history of ingestion of calcium rich
compounds, concordant biochemical findings, and exclu-
sion of other causes especially primary hyperparathyroid-
ism and hypercalcemia of malignancy. The reported intake
of calcium bicarbonate ranges from 2.5 grams (5 tablets)
to 20 grams per day. Parathyroid hormone (PTH) levels
are suppressed and undergo a rapid rebound increase
within hours of the decrease in serum calcium and peaks
approximately 1 week later with a subsequent return to
normal levels [6,11].
At the level of the biochemical markers, MAS patients
used to present with increased in serum phosphorus
values due to the ingestion of phosphorus-rich milk
together with the suppression of PTH that leads to
reduced phosphorus excretion. MAS secondary to cal-
cium carbonate supplementation could present with
normal to low serum phosphorus values. In these
patients, there is no phosphorus supplementation and
the calcium carbonate acts as phosphate binder [12,13].
The presentation in 50 percent of patients is acute and
symptomatic hypercalcemia. In the chronic form, MAS is
usually asymptomatic, with incidental finding of hyper-
calcemia and renal failure.
The complications associated with milk alkali syndrome
are metastatic calcifications, pancreatitis and reversible
Table 1. The case happened in Staten Island University Hospital.
Admission 2 days 7 days 1 month after discharge
Calcium (mg/dl) 13.8 10.1 8.4 8.3
Phosphorus (mg/dl) 5.7 5.5 4
Albumin (g/dl) 1.9 2.3 2.4
BUN (mg/dl) 112 98 72 25
Crea (mg/dl) 8.3 7.8 6.2 1.5
GFR 6 7 9.1 47
Na (meq/l) 137 129 136 135
K (meq/l) 5.6 4.9 3.7 4
Cl (mg/l) 97 96 101 103
Bicarbonate (mg/l) 37 22 24 23
Hemoglobin (g/dl) 11.8 9.1 8.2
Hematocrit (%) 33 30.1 23.9
pH 7.67
PTH (pg/ml) 11.3
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management, withdrawal of the offending agent and
intravenous volume expansion are the most important
initial steps. Usually, these interventions will reverse the
hypercalcemia and the alkalosis. Renal function could
return to normal if the diagnosis of MAS is made early in
the course of the disease. Hemodialysis may be required in
someclinical settings. Inpatients presentingwith veryhigh
serum calcium levels, the addition of furosemide, pami-
dronate and hydrocortisone may be helpful. Bispho-
sphonates should be used cautiously in MAS since bone
resorption is not thought to play an important role in the
pathogenesis of this syndrome, and the usage of bispho-
sphonates has been complicated in several cases by
symptomatic hypocalcemia requiring intravenous calcium
supplementation even in cases with initially very high
serum calcium levels [17].
Conclusion
Although MAS has been frequently reported in the recent
medical literatures (more than 54 patients have been
reported from 1983 through 2004), this syndrome
remains under diagnosed due to several reasons. First, it
is occurring in a wider medical spectrum than the former
association with the treatment of peptic ulcer disease.
Second, the incidence is underestimated in medical
practice. Third, the question of over-the-counter medica-
tions is not frequently asked during a medical encounter.
Although, our case report does not seem interesting as far
as rarity, we opted to write in order to increase the
awareness over the reemergence of MAS, especially that its
under diagnosis was obvious in the case reports published
(three of these 54 patients underwent parathyroid gland
exploration, 20 had permanent renal function impair-
ment) [11]. Given that calcium has replaced milk products
as main source of calcium, we find that it could be
beneficial to give a new nomenclature for this “modern
version” of MAS. “Calcium alkali syndrome”, as suggested
by kaklamanos et al. [18], would be an appropriate name.
This new nomenclature could lead to an increase in
awareness of this diagnosis and underlines the differences
between the “Old” and the “New” MAS.
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